TIMNano introduces a unique GI cancer immunotherapy through a safe and targeted nanomedical solution that overcomes T-cell exhaustion.
As cancer evolves, so must our tools. The rising challenge of immune-resistant tumors demands therapies that don’t just attack – they retrain the body’s own defenses.
TIMNano is developing a next-generation nano-immunotherapy platform, based on targeted biodegradable nanoparticles that deliver immunomodulators directly to dendridic cells, stimulating both T and B cell responses for long-lasting tumor destruction.
This dual-arm immune strategy offers a cost-efficient, scalable and deeply personalized therapeutic approach – leveraging bioprinted tumors and computer-aided drug design.
TIMNano could target:
• Personalized cancer vaccines using 3D-bioprinted tumor models
• Immune cell stimulation (T cells; B cells, dendritic cells)
• Long-lasting anti-tumor immunity
• Potential synergy with checkpoint inhibitors or CAR-T therapies
